[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Savara Inc (SVRA)

Savara Inc (SVRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,043,078
  • Shares Outstanding, K 204,927
  • Annual Sales, $ 0 K
  • Annual Income, $ -118,840 K
  • EBIT $ -134 M
  • EBITDA $ -136 M
  • 60-Month Beta 0.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.06

Options Overview Details

View History
  • Implied Volatility 284.99% (-4.84%)
  • Historical Volatility 52.13%
  • IV Percentile 54%
  • IV Rank 20.56%
  • IV High 1,135.35% on 03/19/26
  • IV Low 64.88% on 05/20/26
  • Expected Move (DTE 20) 0.55 (10.63%)
  • Put/Call Vol Ratio 1.85
  • Today's Volume 683
  • Volume Avg (30-Day) 239
  • Put/Call OI Ratio 0.75
  • Today's Open Interest 2,923
  • Open Int (30-Day) 3,615
  • Expected Range 4.65 to 5.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.15
  • Number of Estimates 4
  • High Estimate $-0.14
  • Low Estimate $-0.15
  • Prior Year $-0.14
  • Growth Rate Est. (year over year) -7.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.70 +10.76%
on 05/19/26
5.44 -4.41%
on 05/05/26
+0.35 (+7.22%)
since 04/29/26
3-Month
4.70 +10.76%
on 05/19/26
6.24 -16.67%
on 04/14/26
-0.82 (-13.62%)
since 02/27/26
52-Week
1.92 +170.83%
on 05/29/25
7.01 -25.77%
on 12/12/25
+3.06 (+143.56%)
since 05/28/25

Most Recent Stories

More News
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team...

SVRA : 5.20 (+2.16%)
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking...

SVRA : 5.20 (+2.16%)
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

-- Data Were Presented at the American Thoracic Society (ATS) International Conference 2026 -- -- All Patients Receive Molgramostim During the OL Treatment Period;...

SVRA : 5.20 (+2.16%)
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

-- Data Were Presented in an Oral Presentation at the American Thoracic Society (ATS) International Conference 2026 --

SVRA : 5.20 (+2.16%)
Savara Reports First Quarter Financial Results and Provides Business Update

Achieved Regulatory Milestones for the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP): ...

SVRA : 5.20 (+2.16%)
Savara's Regulatory Timeline Faces Its First Real Market Test Tomorrow

Barchart Research What to Expect from SVRA Earnings SVRA Generated May 11, 2026 Current Price $5.14 EPS Estimate $$-0.14 Consensus Rating Strong Buy Average Move 5.61% Savara's Regulatory Timeline Faces...

SVRA : 5.20 (+2.16%)
Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference

Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team...

SVRA : 5.20 (+2.16%)
Savara Announces New Employment Inducement Grant

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On April...

SVRA : 5.20 (+2.16%)
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

-- Prescription Drug User Fee Act (PDUFA) Target Action Date Extended by Three Months to November 22, 2026 --

SVRA : 5.20 (+2.16%)
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference

-- All Presentations Include New Data from the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP), Including Data from...

SVRA : 5.20 (+2.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States.

See More

Key Turning Points

3rd Resistance Point 5.53
2nd Resistance Point 5.39
1st Resistance Point 5.30
Last Price 5.20
1st Support Level 5.06
2nd Support Level 4.92
3rd Support Level 4.82

See More

52-Week High 7.01
Last Price 5.20
Fibonacci 61.8% 5.06
Fibonacci 50% 4.46
Fibonacci 38.2% 3.86
52-Week Low 1.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.